You’re actually highlighting the beauty of the Roswell deal—time⏱️…
The most exciting aspect of acquiring the Roswell DC platform is that we are already years into its development and clinical investigation as a combo agent. When the NWBO press release was published, we were already in PII which took years to achieve!
When the news quoted and linked below was first published in 2020, the ongoing DC trials had not even started yet. Today, we know that the Phase I Roswell trials were successful and advanced to Phase II, with funding that includes peer-reviewed U.S. government grants.
The trials at Roswell resulted from peer-reviewed research that also took years …NWBO was quite fortunate to acquire the Roswell DC platform at Phase II, and those trials involve more than one distinct type of cancer too!
“Our approach overcame both primary, or initial, and acquired resistance, and we also saw evidence of tumor-specific systemic immunological memory, suggesting that this strategy may generate long-term anticancer responses even against hard-to-treat melanoma and breast tumors.”
I would argue that all scientific and regulatory milestones relevant to “cancer treatment” will swiftly become relevant for investors. The ‘Health & Wealth’ NWBO investment rationale is grounded in science and clinical data, which will ultimately outweigh OTC market manipulation as more data emerge and more peer-reviewed analyses further validate the crucial role DC platforms may play in developing targeted, less toxic combination therapies as SoC for a range of diseases.
While I’m not an expert in the pharma industry or any financial or medical field—and I don’t make specific predictions—I would suggest that there is evidence supporting the expectation of multiple catalysts unfolding in swift succession, rather than just one, such as the MHRA decision…
I’d direct your attention to page 28 of the recent SEC filing. The full document is publicly available, and anyone can access it directly on the SEC.gov site.
The significance of the “contract” references relates to combination therapies, which arguably may be the most meaningful aspect of NWBO from a shareholder perspective (speaking as a shareholder myself).
Currently, we already know that two of the novel platform technologies owned by NWBO are in combo trials at UCLA and at Roswell Park. The combo trials include Merck’s pembrolizumab, the studies have reached PII, interim efficacy data are beginning to emerge, and the three combo studies (one at UCLA and two at Roswell) are supported by continuing peer-reviewed grants awarded by the U.S. NIH and the U.S. DoD.
The references to “contracts” in the10-Q are particularly intriguing, considering what we already know, and we can reasonably expect further details to emerge. Given that these references appear in an official SEC filing, they are factual statements, suggesting that significant news may be forthcoming.
Market Data 
Markets 
AI
